Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | RBP4 | P02753 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 8/20 | 0.40 |
| ▸ | EP300 | Q09472 | 7/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17878107 | 0.90 | MAPK1 (0.42) | ESR2RBP4MAPK1ADORA1NR1H2 | |
| SCHEMBL4792110 | 0.90 | ADORA1 (0.46) | ESR2RBP4MAPK1ADORA1NR1H2 | |
| SCHEMBL25430237 | 0.89 | ADORA1 (0.43) | ESR2RBP4MAPK1ADORA1NR1H2 | |
| SCHEMBL29386147 | 0.86 | RBP4 (0.42) | ESR2RBP4MAPK1ADORA1NR1H2 | |
| SCHEMBL17870541 | 0.85 | RBP4 (0.39) | ESR2RBP4MAPK1ADORA1NR1H2 | |
| SCHEMBL4761427 | 0.84 | ADORA1 (0.51) | ESR2RBP4ADORA1NR1H2CREBBP | |
| SCHEMBL4761735 | 0.84 | RBP4 (0.42) | ESR2RBP4MAPK1ADORA1NR1H2 | |
| SCHEMBL17870535 | 0.84 | RBP4 (0.39) | ESR2RBP4MAPK1ADORA1NR1H2 | |
| SCHEMBL17868654 | 0.84 | ESR2 (0.46) | ESR2MAPK1ADORA1NR1H2CREBBP | |
| SCHEMBL10296218 | 0.84 | ESR2 (0.43) | ESR2MAPK1ADORA1NR1H2CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020198583-A1 | BICYCLIC JAK INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2020-10-01 | — | — | WO | disclosed |
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE12, PDE10A | ESR2 4207/4885RBP4 1377/4885MAPK1 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.